Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ReViral
Biotech
Pfizer axes another RSV med picked up in $525M ReViral buy
In another blow to its $525 million ReViral buy, Pfizer has ended development of sisunatovir, an oral inhibitor designed to treat RSV.
Gabrielle Masson
Oct 8, 2024 4:58pm
Pfizer snaps up rights to RSV therapy left behind in ReViral buy
Dec 19, 2022 11:23am
Pfizer nabs RSV biotech ReViral in quick $525M bolt-on
Apr 7, 2022 8:27am
RSV specialist ReViral hires ex-Dova leader as CEO
Jun 11, 2019 9:22am
ReViral raises $55M to run midphase RSV clinical trials
Aug 1, 2018 3:09am
British biotech ReViral hits goals in early RSV test
Feb 5, 2018 5:23am
